Status:
COMPLETED
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Lead Sponsor:
Hoffmann-La Roche
Collaborating Sponsors:
Trimeris
Conditions:
HIV Infections
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the signs and symptoms associated with Fuzeon injection (90mg sc) using the B2000 needle-free injection device, in HIV-1 positive patients experienced to Fuzeon treatment, but...
Eligibility Criteria
Inclusion
- adult patients \>=16 years of age;
- current or former Fuzeon user who may benefit from needle-free administration of Fuzeon;
- naive to use of the B2000 device;
- positive test results for human immunodeficiency virus infection.
Exclusion
- patients naive to Fuzeon;
- inability to self-inject Fuzeon, or no reliable caregiver to administer injections;
- evidence of active, untreated, opportunistic infections.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT00337701
Start Date
June 1 2006
End Date
January 1 2007
Last Update
November 3 2015
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294-2050
2
Phoenix, Arizona, United States, 85006
3
Phoenix, Arizona, United States, 85012
4
Fountain Valley, California, United States, 92708